Sweetgreen, Urogen, CoreWeave, Allegro, Dexcom: Trending by Analysts

Analysts are intrested in these 5 stocks: ( (SG) ), ( (URGN) ), ( (CRWV) ), ( (ALGM) ) and ( (DXCM) ). Here is a breakdown of their recent ratings and the rationale behind them.

Sweetgreen is catching the attention of analysts as they initiate coverage with a ‘Buy’ recommendation, highlighting a potential recovery in the second half of the year. Despite recent challenges, such as a significant drop in stock value, the company is expected to bounce back due to improvements in operations and strategic initiatives like Infinite Kitchens. Analysts are optimistic about Sweetgreen’s long-term growth prospects, especially with its strong brand and leadership in automation, which could drive a positive re-rating of its shares.

Urogen Pharma has received a boost from analysts following the FDA approval of its bladder cancer treatment, ZUSDURI. This approval marks a significant milestone for the company, leading to an upgrade to ‘Buy’ with a price target of $50. The treatment offers a new alternative for patients, and the positive trial results have increased confidence in Urogen’s future revenue growth. Analysts are particularly enthusiastic about the company’s potential to reach profitability by the second half of 2026, driven by the expected success of ZUSDURI.

CoreWeave, Inc. has seen a mixed response from analysts, who have downgraded the stock to ‘Hold’ despite raising the price objective. The company’s recent stock surge and premium valuation have led analysts to believe that much of the near-term upside is already priced in. However, positive developments, such as new customer agreements and a lower cost of capital, support the raised price objective. The AI infrastructure market remains robust, but analysts caution about the company’s high capital expenditure and funding needs.

Allegro MicroSystems is gaining attention as analysts reinstate coverage with a ‘Buy’ rating, driven by its leadership in auto sensor technology and opportunities in the expanding electric vehicle market. The company is well-positioned to benefit from a cyclical recovery in the auto industry and is expected to outgrow its peers. Analysts see significant potential for earnings growth through market share gains and margin expansion, although they note potential risks related to auto demand recovery and competition.

Dexcom is being recommended as a ‘Buy’ by analysts, who are optimistic about its prospects in the continuous glucose monitoring market. The company’s innovative technology and expanding market opportunities in diabetes management are expected to drive significant revenue growth. Analysts highlight the potential for increased adoption in the type 2 diabetes market and anticipate margin improvements from new product developments. The stock is seen as having strong growth potential, with a price target set at $102.